{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erlotinib+placebo", "query": { "intervention": "Erlotinib placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 54, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erlotinib+placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T19:53:36.341Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00754494", "title": "Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenomatous Polyp", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage I Colon Cancer", "Stage I Rectal Cancer", "Stage IIA Colon Cancer", "Stage IIA Rectal Cancer", "Stage IIB Colon Cancer", "Stage IIB Rectal Cancer", "Stage IIC Colon Cancer", "Stage IIC Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2008-07", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-01-06", "last_synced_at": "2026-09-28T19:53:36.341Z", "location_count": 3, "location_summary": "Long Beach, California • Orange, California • Chicago, Illinois", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00754494" }, { "nct_id": "NCT00570258", "title": "Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 27, "start_date": "2006-09", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2021-03-30", "last_synced_at": "2026-09-28T19:53:36.341Z", "location_count": 6, "location_summary": "Jonesboro, Arkansas • Little Rock, Arkansas • Springdale, Arkansas + 3 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00570258" }, { "nct_id": "NCT00777309", "title": "A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "ARQ 197", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2008-09", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-09-28T19:53:36.341Z", "location_count": 18, "location_summary": "Burbank, California • Santa Monica, California • Torrington, Connecticut + 14 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Torrington", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00777309" }, { "nct_id": "NCT00779389", "title": "Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Dasatinib + Placebo", "type": "DRUG" }, { "name": "Erlotinib plus Dasatinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2009-01", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2016-01-13", "last_synced_at": "2026-09-28T19:53:36.341Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00779389" }, { "nct_id": "NCT00026338", "title": "Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NCIC Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 569, "start_date": "2001-10-29", "completion_date": "2009-02-10", "has_results": false, "last_update_posted_date": "2020-04-02", "last_synced_at": "2026-09-28T19:53:36.341Z", "location_count": 74, "location_summary": "Tucson, Arizona • Springdale, Arkansas • Berkeley, California + 63 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026338" }, { "nct_id": "NCT04172779", "title": "Erlotinib for Hepatocellular Carcinoma Chemoprevention", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cirrhosis, Liver", "Advanced Liver Fibrosis" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-12", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-09-28T19:53:36.341Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04172779" }, { "nct_id": "NCT01456325", "title": "A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Onartuzumab (MetMab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 494, "start_date": "2012-01", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-28T19:53:36.341Z", "location_count": 56, "location_summary": "Chandler, Arizona • Hayward, California • Modesto, California + 47 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Hayward", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01456325" }, { "nct_id": "NCT02194738", "title": "Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IB Lung Non-Small Cell Carcinoma AJCC v7", "Stage II Lung Non-Small Cell Cancer AJCC v7", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Clinical Observation", "type": "OTHER" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7458, "start_date": "2014-09-26", "completion_date": "2027-09-21", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-09-28T19:53:36.341Z", "location_count": 1655, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02194738" }, { "nct_id": "NCT01393821", "title": "Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dermatologic Complications", "Malignant Neoplasm", "Pain" ], "interventions": [ { "name": "menadione topical lotion", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2012-01-23", "completion_date": "2018-07-14", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-09-28T19:53:36.341Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01393821" }, { "nct_id": "NCT00976677", "title": "Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2010-01", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2014-05-30", "last_synced_at": "2026-09-28T19:53:36.341Z", "location_count": 108, "location_summary": "Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 65 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976677" } ] }